David E. Gerber
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 121
- Cancer Immunotherapy and Biomarkers 55
- Lung Cancer Research Studies 24
- Colorectal Cancer Treatments and Studies 15
-
- Lung Cancer Treatments and Mutations 71
- Lung Cancer Diagnosis and Treatment 41
- Co-authors
- Lorraine Pelosof (2 shared papers)Yang Xie (40 shared papers)John D. Minna (11 shared papers)Joan H. Schiller (21 shared papers)Julie R. Brahmer (24 shared papers)Shaheen Khan (8 shared papers)Sandi L. Pruitt (18 shared papers)Scott Gettinger (18 shared papers)
- Journals
- Journal of Clinical Oncology (61 papers)Journal of Thoracic Oncology (22 papers)Lung Cancer (16 papers)Clinical Lung Cancer (15 papers)International Journal of Radiation Oncology*Biology*Physics (12 papers)
- Partner nations
- United StatesCanadaChina
In The Last Decade
David E. Gerber
281 papers receiving 9.8k citations
David E. Gerber's Hit Papers
Peers
Comparison fields: 5 of 145
- Oncology 4.4k
- Pulmonary and Respiratory Medicine 3.4k
- Cancer Research 844
- Immunology 1.1k
- Internal Medicine 162
Countries citing papers authored by David E. Gerber
This map shows the geographic impact of David E. Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David E. Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David E. Gerber more than expected).
Fields of papers citing papers by David E. Gerber
This network shows the impact of papers produced by David E. Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David E. Gerber. The network helps show where David E. Gerber may publish in the future.
Co-authors
The 25 scholars most cited alongside David E. Gerber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 299 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study Hit paper breakdown → | 2016 | 719 |
| 2 | Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 690 |
| 3 | Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment Hit paper breakdown → | 2010 | 470 |
| 4 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 406 |
| 5 | 2016 | 357 | |
| 6 | Targeted therapies: a new generation of cancer treatments. | 2008 | 342 |
| 7 | Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2011 | 327 |
| 8 | 2014 | 218 | |
| 9 | 2010 | 171 | |
| 10 | 2019 | 165 | |
| 11 | 2018 | 151 | |
| 12 | 2018 | 142 | |
| 13 | 2018 | 139 | |
| 14 | 2013 | 127 | |
| 15 | 2019 | 119 | |
| 16 | 2006 | 119 | |
| 17 | 2013 | 118 | |
| 18 | 2016 | 117 | |
| 19 | 2008 | 112 | |
| 20 | 2017 | 105 |
About David E. Gerber
David E. Gerber is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology and Public Health, Environmental and Occupational Health, having authored 299 papers that have together received 10.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (71 papers), Cancer Immunotherapy and Biomarkers (55 papers), Lung Cancer Diagnosis and Treatment (41 papers), Lung Cancer Research Studies (24 papers), Ethics in Clinical Research (20 papers), Phagocytosis and Immune Regulation (18 papers), Cancer Genomics and Diagnostics (17 papers) and Colorectal Cancer Treatments and Studies (15 papers). The work is most often cited by research in Oncology (4.4k citations), Pulmonary and Respiratory Medicine (3.4k citations), Cancer Research (844 citations), Immunology (1.1k citations) and Internal Medicine (162 citations). David E. Gerber has collaborated with scholars based in United States, Canada and China. Frequent co-authors include Lorraine Pelosof, Yang Xie, John D. Minna, Joan H. Schiller, Julie R. Brahmer, Shaheen Khan, Sandi L. Pruitt, Scott Gettinger, Laura Q.M. Chow and Scott Antonia. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Clinical Lung Cancer and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.